Eyepoint Pharmaceuticals Inc (EYPT)
EyePoint Pharmaceuticals Inc. is a NASDAQ-listed common stock issuer focused on developing and commercializing therapies for serious retinal diseases. The company’s pipeline is built around its proprietary Durasert E bioerodible platform, which is designed for sustained drug delivery inside the eye. Its lead candidate, DURAVYU, combines vorolanib, a selective tyrosine kinase inhibitor, with Durasert E and is in Phase 3 clinical trials for wet age-related macular degeneration and diabetic macular edema. EyePoint’s development program also includes EYP-2301, a TIE-2 agonist formulated with Durasert E and currently in pre-clinical development. Founded in 2000 and headquartered in Watertown, Massachusetts, the company changed its name from EyePoint Pharmaceuticals, Inc. to EyePoint, Inc. in December 2025.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-EYPT
|
$12.80
|
-2.7% Downside
|
Fair
|
$40.50
|
207.9% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-4.0x
|
4.8x
|
144.1x
|
1.061 B
|
897.3 M
|
2.1%
|
74.2%
|
2.9
|
—
|
100.0%
|
